title: Enhanced contractility of small blood vessels in JNK knockout mice.
abstract: The c-Jun N-terminal kinases (JNKs) form a subfamily of the mitogen-activated protein kinases (MAPK). These signalling pathways regulate various processes such as mitosis, cellular differentiation, stress response or apoptosis in multicellular organisms. There is rising evidence about the role of JNKs activities in neurodegenerative and metabolic diseases as well as in immunological disorders. The physiological functions of JNKs, however, remain to be elucidated. Recent data have demonstrated an essential role of JNKs in the cardiovascular system and the regulation of carbon hydrate and glucose metabolism. Therefore, we have investigated the contractility of blood vessels in mice with genetically deleted JNK1, JNK2, JNK3 and JNK2+3 isoforms and their respective wildtypes. The contractility of the isolated segments from A. carotis communis was measured by small blood vessel wire myograph. Contraction induced by 80 mM KCl was significantly increased in arteries from JNK2+3 double knockout compared to controls and single knockouts. The maximal contraction generated by the alpha-agonists phenylephrine or noradrenaline (10 microM) was significantly enhanced in JNK2+3 knockout arteries compared with arteries from the remaining strains. Inhibition of NOS by Nw-nitro-l-arginine did not change the pattern of vasoconstriction, but vasoconstriction by noradrenaline following NOS inhibition was significantly enhanced in the arteries from JNK2+3 double knockout mice. In conclusion, genetic deletion of JNK2+3 in mice results in altered contractility of carotid arteries and this might depend on the function of the smooth muscles rather than on the endothelium. These findings have implications for the long-term treatment with pharmacological JNK inhibitors for neurodegenerative or metabolic diseases such as stroke or diabetes.
authors.affiliation: Department of Physiology, Kaunas University of Medicine, Mickeviciaus 9, LT-44307 Kaunas, Lithuania. alelaukeviciene@lycos.com
authors.forename: Ale
authors.initials: A
authors.lastname: Laukeviciene
authors.forename: Stephan
authors.initials: S
authors.lastname: Brecht
authors.forename: Egidijus
authors.initials: E
authors.lastname: Kevelaitis
authors.forename: Thomas
authors.initials: T
authors.lastname: Herdegen
mesh_terms: D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology*; D015971:Gene Expression Regulation, Enzymologic; D048031:JNK Mitogen-Activated Protein Kinases / Q000172:deficiency* / Q000235:genetics; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D009638:Norepinephrine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D020033:Protein Isoforms / Q000172:deficiency / Q000235:genetics; D014661:Vasoconstriction / Q000187:drug effects / Q000235:genetics / Q000502:physiology*
chemical_list: D020033:Protein Isoforms; D010656:Phenylephrine; D019001:Nitric Oxide Synthase; D048031:JNK Mitogen-Activated Protein Kinases; D009638:Norepinephrine